Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | ALK-positive NSCLC: CNS progression

Sanjay Popat, PhD, MBBS, FRCP, Royal Marsden NHS Foundation Trust, London, UK, discusses the risk of CNS progression in patients with ALK-positive metastatic Non-Small cell lung cancer (NSCLC), and how we can determine and reduce the risk. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.